Thomas E. Hutson, DO, Pharm.D., FACP

Articles

An Individualized Approach to Treating Advanced RCC

July 31st 2023

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.

The Evolving Advanced RCC Treatment Landscape

June 26th 2023

Researcher and clinician, Dr. Thomas Hutson reflects on the modern patient journey and shares his experience treating people with advanced RCC. Through the years, the advanced RCC treatment landscape has evolved significantly. In this two-part series brought to you by Eisai Inc., hear from oncologist Thomas Hutson, DO as he reflects on best practices for evaluating today’s treatment options.

An Economic Evaluation of Cabazitaxel Versus a Second Androgen Receptor‑targeted Agent (ARTA) for Patients with Metastatic Castration‑resistant Prostate Cancer Previously Treated with Docetaxel and an ARTA: the United States Payer Perspective

December 16th 2022

Dr Thomas Hutson reviews recently published data on patient outcomes and estimated healthcare costs associated with use of third-line cabazitaxel versus a second ARTA in patients with metastatic castration-resistant prostate cancer (CRPC).

Dr. Hutson on Safety Considerations With Cabozantinib in mRCC

May 24th 2021

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Dr. Hutson on Challenges With Targeted Therapy in Non-Clear Cell RCC

January 8th 2021

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.

Dr. Hutson on Remaining Questions With the Durability of Immune Responses in RCC

November 12th 2020

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Dr. Hutson on Lenvatinib/Everolimus Combo in RCC

November 5th 2016

Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).

Dr. Thomas Hutson on Drug Sequencing in Renal Cell Carcinoma

April 24th 2015

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Dr. Hutson Discusses the Phase III ATLAS Study in RCC

July 18th 2014

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

Dr. Hutson on Tivozanib for Renal Cell Carcinoma

June 13th 2013

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).